Valuation : Collegium Pharmaceutical, Inc.

Market Cap 741M 639M 604M 548M 1.03B 70.76B 1.03B 7.17B 2.76B 35.96B 2.78B 2.72B 114B P/E 2026 *
11.3x
P/E 2027 * 5.83x
Enterprise Value 741M 639M 604M 548M 1.03B 70.76B 1.03B 7.17B 2.76B 35.96B 2.78B 2.72B 114B EV / Sales 2026 *
0.89x
EV / Sales 2027 * 0.88x
Free-Float
77.39%
Yield 2026 *
-
Yield 2027 * -
1 day-0.74%
1 week-3.31%
Current month-7.56%
1 month-12.43%
3 months-33.75%
6 months-36.13%
Current year-50.86%
1 week 22.64
Extreme 22.64
24.11
1 month 22.64
Extreme 22.64
29.65
Current year 22.64
Extreme 22.64
49.31
1 year 22.64
Extreme 22.64
50.79
3 years 20.95
Extreme 20.95
50.79
5 years 14.04
Extreme 14.04
50.79
10 years 7.37
Extreme 7.37
50.79
Manager TitleAgeSince
Chief Executive Officer 51 12/11/2024
Director of Finance/CFO 50 24/05/2021
Chief Tech/Sci/R&D Officer 65 23/03/2022
Director TitleAgeSince
Chairman 69 15/05/2025
Director/Board Member 72 01/02/2014
Director/Board Member 78 01/01/2015
Date Insider Type Main position Quantity % Market Cap. Importance
18/5/26 Sell

Director

-20 0.0001%
15/5/26 Exercice

Director

21,527 0.0664%
14/5/26 Free

Director

8,741 0.0270%
Change 5-day change 1-year change 3-year change Capi.($)
-0.74%-3.31%-41.76%-2.61% 741M
-0.65%-2.93%+47.70%+86.17% 994B
-0.29%-3.51%+49.15%+62.35% 640B
+0.83%+0.26%+17.76%+72.25% 454B
-0.38%-3.59%+28.24%+35.57% 337B
-0.09%-13.54%+10.08%+26.87% 261B
-0.43%-2.48%-2.07%+11.48% 246B
-1.34%-13.70%+33.47%+44.18% 204B
-3.44%-7.51%-20.08%-59.58% 190B
-0.75%-4.82%+21.94%+86.55% 178B
Average -0.73%-5.51%+14.44%+36.32% 350.55B
Weighted average by Cap. -0.51%-4.42%+30.10%+55.17%

Financials

2026 *2027 *
Net sales 836M 721M 682M 619M 1.16B 79.88B 1.17B 8.1B 3.11B 40.6B 3.14B 3.07B 128B 843M 727M 688M 623M 1.17B 80.49B 1.18B 8.16B 3.14B 40.91B 3.16B 3.09B 129B
Net income 72.55M 62.56M 59.21M 53.67M 101M 6.93B 101M 703M 270M 3.52B 272M 266M 11.14B 151M 131M 124M 112M 210M 14.47B 211M 1.47B 564M 7.36B 569M 556M 23.26B
Net Debt - -
Logo Collegium Pharmaceutical, Inc.
Collegium Pharmaceutical, Inc. is a diversified biopharmaceutical company. The Company has developed, licensed, and acquired a portfolio of products for use in the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. Its commercial products include Jornay PM (Jornay), Belbuca, Xtampza ER (Xtampza), Nucynta ER and Nucynta IR (Nucynta Products), and Symproic in the United States. Its Jornay is a central nervous system (CNS) stimulant prescription medicine for the treatment of ADHD. The Belbuca is a buccal film that contains buprenorphine for severe and persistent pain. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone. The Xtampza ER is a pain treatment option designed with abuse deterrent properties. Its portfolio also includes AZSTARYS (serdexmethylphenidate and dexmethylphenidate), a central nervous system (CNS) stimulant prescription medicine used for the treatment of ADHD in people six years of age and older.
Employees
423
Date Price Change Volume
11/09/26 US$22.75 -0.74% 661,300
10/09/26 US$22.92 -1.88% 889,098
09/09/26 US$23.36 -0.04% 1,077,597
08/09/26 US$23.37 -0.68% 1,114,851
04/09/26 US$23.53 -0.72% 901,142
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
22.75USD
Average target price
48.86USD
Spread / Average Target
+114.76%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. COLL Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!